Candriam Luxembourg S.C.A. Increases Stake in AveXis (AVXS)

Candriam Luxembourg S.C.A. grew its holdings in AveXis (NASDAQ:AVXS) by 36.8% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 39,000 shares of the company’s stock after buying an additional 10,500 shares during the period. Candriam Luxembourg S.C.A. owned 0.11% of AveXis worth $4,820,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in AVXS. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of AveXis by 57.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock valued at $137,000 after buying an additional 453 shares during the last quarter. QS Investors LLC purchased a new stake in shares of AveXis in the fourth quarter valued at about $156,000. Public Employees Retirement Association of Colorado purchased a new stake in shares of AveXis in the fourth quarter valued at about $251,000. Silvant Capital Management LLC purchased a new stake in shares of AveXis in the first quarter valued at about $298,000. Finally, Tiverton Asset Management LLC purchased a new stake in shares of AveXis in the first quarter valued at about $307,000. 84.14% of the stock is owned by institutional investors and hedge funds.

Shares of AveXis opened at $217.83 on Friday, according to Marketbeat Ratings. AveXis has a twelve month low of $65.54 and a twelve month high of $217.94. The stock has a market cap of $8.02 billion, a price-to-earnings ratio of -29.92 and a beta of 1.55.

AveXis (NASDAQ:AVXS) last issued its earnings results on Wednesday, May 9th. The company reported ($6.20) earnings per share for the quarter, missing the consensus estimate of ($3.32) by ($2.88). equities analysts anticipate that AveXis will post -9.69 EPS for the current fiscal year.

In other AveXis news, CEO Sean P. Nolan sold 10,000 shares of the company’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $129.47, for a total transaction of $1,294,700.00. Following the transaction, the chief executive officer now directly owns 10,000 shares in the company, valued at $1,294,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP James J. Litalien sold 5,000 shares of the company’s stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $119.44, for a total transaction of $597,200.00. Following the transaction, the vice president now owns 8,800 shares in the company, valued at $1,051,072. The disclosure for this sale can be found here. Insiders have sold 46,780 shares of company stock worth $5,801,268 over the last 90 days. 18.60% of the stock is currently owned by company insiders.

A number of research analysts have recently issued reports on AVXS shares. Zacks Investment Research upgraded shares of AveXis from a “strong sell” rating to a “hold” rating in a research note on Monday, May 7th. Jefferies Group lowered shares of AveXis from a “buy” rating to a “hold” rating in a research note on Wednesday, April 18th. Chardan Capital lowered shares of AveXis from a “buy” rating to a “neutral” rating in a research note on Friday, April 13th. Barclays lowered shares of AveXis from an “overweight” rating to an “equal weight” rating and set a $152.00 price target on the stock. in a research note on Thursday, April 12th. Finally, UBS lowered shares of AveXis from a “buy” rating to a “neutral” rating in a research note on Thursday, April 12th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $123.90.

AveXis Profile

AveXis, Inc, a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.

Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis (NASDAQ:AVXS).

Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply